Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05607498
Registration number
NCT05607498
Ethics application status
Date submitted
27/10/2022
Date registered
7/11/2022
Date last updated
22/09/2023
Titles & IDs
Public title
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Query!
Scientific title
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Query!
Secondary ID [1]
0
0
EMB07X101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced/Metastatic Solid Tumors
0
0
Query!
Relapse/Refractory Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - EMB07
Experimental: EMB-07-Patients with solid tumor - Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
Experimental: EMB07-Patients with lymphoma - Patients with lymphoma will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
Treatment: Drugs: EMB07
EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence and severity of adverse events as assessed by CTCAE V5.0.
Query!
Assessment method [1]
0
0
Incidence and severity of AE.
Query!
Timepoint [1]
0
0
Screening up to 30 days after the last dose.
Query!
Primary outcome [2]
0
0
Incidence of serious adverse events (SAE).
Query!
Assessment method [2]
0
0
Incidence of SAE.
Query!
Timepoint [2]
0
0
Screening up to 30 days after the last dose, or beyond 30 days if SAE is confirmed to be treatment related.
Query!
Primary outcome [3]
0
0
Incidence of dose interruptions.
Query!
Assessment method [3]
0
0
Incidence of dose interruptions of EMB-07 during treatment as a measure of tolerability.
Query!
Timepoint [3]
0
0
Screening up to 30 days after the last dose.
Query!
Primary outcome [4]
0
0
Dose intensity.
Query!
Assessment method [4]
0
0
Actual amount of drug taken by patients divided by the planned amount.
Query!
Timepoint [4]
0
0
Screening up to 30 days after the last dose.
Query!
Primary outcome [5]
0
0
The incidence of DLTs during the first cycle of treatment.
Query!
Assessment method [5]
0
0
The dose limiting toxicities are based on drug related adverse events and are specifically defined in study protocol.
Query!
Timepoint [5]
0
0
First infusion to the end of cycle 1. (each cycle is 28 days).
Query!
Secondary outcome [1]
0
0
Overall response rate.
Query!
Assessment method [1]
0
0
Overall response rate measured by RECIST V1.1, iWCLL-2018, Lugano 2014
Query!
Timepoint [1]
0
0
From the date of dosing untill the date of first documented progression or date of death from any casue, whichever case first, expected average 6 months.
Query!
Secondary outcome [2]
0
0
Area under the serum concentration-time curve (AUC) of EMB-07.
Query!
Assessment method [2]
0
0
Blood samples for serum PK analysis will be obtained (AUC).
Query!
Timepoint [2]
0
0
Through treatment until EOT visit, expected average 6 months.
Query!
Secondary outcome [3]
0
0
Maximum serum concentration (Cmax) of EMB-07.
Query!
Assessment method [3]
0
0
Blood samples for serum PK analysis will be obtained (Cmax).
Query!
Timepoint [3]
0
0
Through treatment until EOT visit, expected average 6 months.
Query!
Secondary outcome [4]
0
0
Trough concentration (Ctrough) of EMB-07.
Query!
Assessment method [4]
0
0
Blood samples for serum PK analysis will be obtained (Ctrough).
Query!
Timepoint [4]
0
0
Through treatment until EOT visit, expected average 6 months.
Query!
Secondary outcome [5]
0
0
Average concentration over a dosing interval (Css, avg) of EMB-07.
Query!
Assessment method [5]
0
0
Blood samples for serum PK analysis will be obtained (Css,avg).
Query!
Timepoint [5]
0
0
Through treatment until EOT visit, expected average 6 months.
Query!
Secondary outcome [6]
0
0
Terminal half-life (T1/2) of EMB-07.
Query!
Assessment method [6]
0
0
Blood samples for serum PK analysis will be obtained (T1/2).
Query!
Timepoint [6]
0
0
Through treatment until EOT visit, expected average 6 months.
Query!
Secondary outcome [7]
0
0
Systemic clearance (CL) of EMB-07.
Query!
Assessment method [7]
0
0
Blood samples for serum PK analysis will be obtained (CL).
Query!
Timepoint [7]
0
0
Through treatment until EOT visit, expected average 6 months.
Query!
Secondary outcome [8]
0
0
Steady state volume of distribution (Vss) of EMB-07.
Query!
Assessment method [8]
0
0
Blood samples for serum PK analysis will be obtained (Vss).
Query!
Timepoint [8]
0
0
Through treatment until EOT visit, expected average 6 months.
Query!
Secondary outcome [9]
0
0
Progression free survival (PFS) of EMB-07 as assessed by RECIST 1.1, iWCLL-2018, Lugano 2014
Query!
Assessment method [9]
0
0
From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months.
Query!
Timepoint [9]
0
0
Through treatment discontinuation: an average of 6 months
Query!
Secondary outcome [10]
0
0
Incidence and titer of anti-drug antibodies stimulated by EMB-07.
Query!
Assessment method [10]
0
0
Antibodies to EMB-07 will be assessed to evaluate potential immunogenicity.
Query!
Timepoint [10]
0
0
Up to End of Treatment Follow Up Period (30 days after the last dose)
Query!
Eligibility
Key inclusion criteria
1. Willing and able to provide signed and dated informed consent prior to any
study-related procedures and willing and able to comply with all study procedures.
2. Male or female, and aged = 18 years
3. Treatment group A: Patients with histologically or cytologically locally advanced
unresectable or metastatic solid tumors limiting to triple-negative breast cancer,
lung adenocarcinoma, ovarian cancer, pancreatic cancer, colorectal cancer, gastric
cancer, prostate cancer, bladder cancer, and uterus cancer. Treatment group B:
Patients with histologically or cytologically relapse/refractory lymphoma limiting to
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell
lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL).
4. Treatment group A: Standard therapies do not exist, or are no longer effective, or are
not tolerable or accessible to the patient measurable or evaluable disease per RECIST
V1.1. Treatment group B: Presence of at least one two-dimensional measurable lesion
confirmed by imaging (CT or MRI) (either lymph nodes lesions with any long diameter >
1.5 cm or extranodal lesions with any long diameter > 1.0 cm); for CLL patients whose
baseline imaging evaluation determined that no two-dimensional measurable lesions,
their peripheral blood monoclonal B lymphocytes should be = 5.0×109/L.
5. Patients must provide archival tumor samples, or a biopsy will be required if archival
tumor sample is not available. Archival tumor sample must be taken = 2 years prior to
screening, otherwise a fresh tumor biopsy at screening is required.
6. ECOG performance status 0 or 1
7. Adequate organ function to participate in the trial.
8. Recovery from adverse events (AEs) related to prior anticancer therapy.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Prior treatment with any agent targeting ROR1.
2. History of Grade 4 immune-related adverse events (irAEs) or irAEs requiring
discontinuation of prior therapies.
3. Patient with primary central nervous system (CNS) malignancy or symptomatic CNS
metastases. Patients with solid tumors with CNS metastases are eligible if they do not
need to receive local radiation treatment at the discretion of investigator or if
radiation therapy for CNS metastases is completed = 4 weeks prior to study treatment.
4. Anticancer therapy or radiation < 5 half-lives or 4 weeks (whichever is shorter) prior
to study treatment.
5. Abuse on alcohol, cannabis-derived products, or other drugs.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/03/2026
Query!
Actual
Query!
Sample size
Target
150
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
Peninsula and South Eastern Haematology and Oncology Group - Frankston
Query!
Recruitment hospital [2]
0
0
One Clinical Research - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
- Frankston
Query!
Recruitment postcode(s) [2]
0
0
- Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
China
Query!
State/province [1]
0
0
Hunan
Query!
Country [2]
0
0
China
Query!
State/province [2]
0
0
Baoding
Query!
Country [3]
0
0
China
Query!
State/province [3]
0
0
Beijing
Query!
Country [4]
0
0
China
Query!
State/province [4]
0
0
Bengbu
Query!
Country [5]
0
0
China
Query!
State/province [5]
0
0
Guangzhou
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Harbin
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Shandong
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Tianjin
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and
tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended
Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma
activity of EMB-07 will also be assessed.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05607498
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Xiaodong Sun
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+8618512158506
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05607498
Download to PDF